Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

María Elena Santolaya, Miguel L. O'Ryan, María Teresa Valenzuela, Valeria Prado, Rodrigo F. Vergara, Alma Muñoz, Daniela Toneatto, Gabriela Graña, Huajun Wang, Peter M. Dull

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

We previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero®), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. participants in this extension study provided an additional blood sample 18-24 mo after last vaccine dose, to assess persistence of serum bactericidal activity with human complement (hSBA), and to compare with age-matched 4CMenB-naïve controls. In the original study, one month after one 4CMenB dose, 93% of subjects had seroprotective hSBA titers (≥4) against indicator serogroup B strains for individual vaccine antigens (fHbp, NadA and NZoMV), increasing to ~100% after two or three doses. After 18-24 mo, 62-73% of subjects given one dose had titers ≥4 against the three antigens, significantly lower rates than after two (77-94%) or three (86-97%) doses. only proportions with titers ≥ 4 against NZoMV were significantly different between the two (77%) and three (90%, p < 0.0001) dose groups. these results confirm that two doses of 4CMenB, administered 1 to 6 mo apart, provide good levels of bactericidal activity against serogroup B meningococci, which were sustained at least 18-24 mo in over 64% of adolescents for all three tested vaccine-related antigens.
Original languageAmerican English
Pages (from-to)2304-2310
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume9
Issue number11
DOIs
StatePublished - 1 Jan 2013

Keywords

  • Adolescents
  • Antibodies
  • Meningococcal
  • Persistence
  • Serogroup B
  • Vaccine

Fingerprint Dive into the research topics of 'Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine'. Together they form a unique fingerprint.

Cite this